



## **CRESCENDO DIGITAL PATHOLOGY WORKSTATION – AN INTEGRATED IMAGING SOLUTION**

Emerging technologies in the area of digital pathology are increasingly replacing conventional systems, especially in the United States, where digital pathology technologies are increasingly replacing traditional solutions due to competitive technical aspects such as accessibility, image storage, and high-resolution images. Although digital pathology systems are in high demand at clinical labs, the Food and Drug Administration (FDA) is now planning to discuss further and subsequently make public health issues recommendation on the use of digital whole slide imaging systems in diagnostic surgical pathology. The FDA is now looking for advice from experts in the field of digital pathology imaging and systems to regulate a few technical aspects.

BioImagene Inc., a company headquartered at Sunnyvale, California , and an active developer of digital pathology solutions has announced the launch of its new product at the CAP'09 meeting. Crescendo Digital Pathology Workstation was launched in an effort to offer decision support solutions that could turn a pathologist into a diagnostician. The systems integrates information from laboratory information systems (LIS), radiology picture archive and communication system (PACS) images, gross images, online references, electronic medical records and relative patient information with digital pathology images using data integration methodologies such as XML and HL7 for error-free diagnosis. The system can be used to simultaneously view multiple pathology images with better image navigation. It also combines features of Virtuoso, an online digital pathology workflow application along with its disease-specific Companion Algorithms for quantitative assessment of several biomarkers. The system has an in-built platform that helps in peer-review of digital slides through Internet connection.

The company further explains that Crescendo data integration capability is an effective decision-making support for a pathologist who is the primary decision maker. Being one of the leading players in the area of digital pathology, the company has been actively involved in design and launch of innovative digital solutions for pathologists. Each year the company is actively involved in at least two major product upgrades in its products including Virtuoso and iScan Coreo, a bright field scanning system. The company is currently planning to release iScan Concerto, a unique combination of fluorescence and bright-field scanner in March 2010, along with other developments made over the past one year.

Amidst FDA intervention in regulating digital pathology solutions, the company is actively involved in a healthy relationship with FDA. It is significant to note that the FDA

expert panel included key persons from the company. Further, company sources say, "BioImagene was encouraged that the FDA and the expert panel it convened was enthusiastic about digital pathology as a technology and its potential for improving pathology diagnoses and patient care. BioImagene has worked with the FDA from the very beginning and received its first 510K clearance for a Her2 algorithm in November 2008, and currently has several other algorithms under review by the FDA. BioImagene has a rich pipeline of image analysis algorithms which will also be submitted to the FDA for clearance." However, Crescendo DPW is currently not approved by the FDA.

Details: Ben Navon, Public Relations, Schwartz Communications Inc., 230 Third Avenue, Waltham, MA 02451. Phone: 781-684-0770. Fax: 781-684-6500. E-mail: [BNavon@schwartz-pr.com](mailto:BNavon@schwartz-pr.com). URL: [www.bioimagene.com/products\\_solutions/crescendo.html](http://www.bioimagene.com/products_solutions/crescendo.html).